Skip to main content
    O

    Oncology Institute Inc (TOI)

    Official site

    HEALTHCARE • MEDICAL CARE FACILITIES • NASDAQ

    $5.13
    +0.27 (+5.56%)

    Market Cap: $512.91M

    Last updated: Aug 03, 2026 at 7:34 PM ET

    Oncology Institute Inc (TOI) Financials: Revenue, Profit and Cash Flow

    Updated Sep 30, 2026. Financial statements from company filings, amounts in US dollars.

    Oncology Institute reported revenue of $502.73M for the fiscal year ended Dec 31, 2025, up 27.8% from the year before. That year, net income was -$60.61M with a net margin of -12.1%, operating cash flow was -$24.59M and free cash flow was -$27.79M. The quarter ended Sep 30, 2026 had revenue of $169.77M and net income of -$15.75M.

    Revenue and Margins

    The operating margin was -7.2% in the fiscal year ended Dec 2025. Over the 7 years to Dec 2025, revenue grew from $113.16M, a compound annual rate of 23.7%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$502.73M+27.8%15.2%-7.2%-12.1%
    Dec 2024$393.41M+21.3%13.7%-15.3%-16.4%
    Dec 2023$324.24M+28.4%18.4%-23.8%-25.6%
    Dec 2022$252.48M+24.4%20.6%-32.5%0.1%
    Dec 2021$203.00M+8.3%20.1%-22.6%-5.4%
    Dec 2020$187.51M+20.7%19.7%-4.4%-7.6%
    Dec 2019$155.41M+37.3%19.3%-1.7%-2.6%
    Dec 2018$113.16MN/A23.2%4.2%3.5%
    Annual, fiscal years ended Dec 2018 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
    Revenue$502.73M$393.41M$324.24M$252.48M$203.00M$187.51M$155.41M$113.16M
    Cost of revenue$426.29M$339.42M$264.67M$200.39M$162.16M$150.64M$125.46M$86.88M
    Gross profit$76.44M$54.00M$59.57M$52.09M$40.85M$36.88M$29.94M$26.28M
    Operating income-$36.08M-$60.12M-$77.02M-$81.95M-$45.86M-$8.20M-$2.64M$4.79M
    Net income-$60.61M-$64.66M-$83.07M$152.00K-$10.93M-$14.32M-$4.02M$3.95M
    EBITDA-$21.01M-$47.41M-$67.05M-$19.14M-$14.21M-$4.96M$307.11K$9.08M
    Fiscal years ended Dec 2018 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$169.77M$161.28M$147.44M$141.96M$136.56M$119.80M$104.41M$100.27M$99.90M$98.58M$94.67M$85.79M
    Gross profitN/AN/A$21.70M$22.77M$18.92M$17.50M$17.25M$14.64M$14.37M$13.03M$11.97M$14.38M
    Operating incomeN/AN/A-$6.51M-$6.91M-$8.05M-$11.21M-$9.91M-$11.93M-$13.85M-$16.36M-$17.97M-$15.29M
    Net income-$15.75M-$9.79M-$2.49M-$7.51M-$16.50M-$17.01M-$19.59M-$13.18M-$16.11M-$15.48M-$19.89M-$18.75M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, total debt of $127.72M exceeded cash and equivalents by $94.16M. Shareholder equity was negative, at -$15.72M, as total liabilities of $180.38M exceeded total assets of $164.66M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
    Total assets$164.66M$172.72M$209.24M$261.67M$203.44M$65.69M$50.00KN/A
    Current assets$112.75M$112.42M$143.49M$130.42M$154.06M$29.72M$21.79MN/A
    Cash and equivalents$33.56M$49.67M$33.49M$14.01M$115.17M$6.00M$25.00KN/A
    Total liabilities$180.38M$169.13M$152.22M$138.49M$99.28M$37.59M$27.30KN/A
    Short-term debt$50.32M$31.12M$20.79M$14.87M$15.74M$18.01M$800N/A
    Long-term debt$77.40M$93.13M$86.83M$80.62M$0$6.56MN/AN/A
    Shareholder equity-$15.72M$3.59M$57.02M$123.17M$104.16M$28.10M$22.70KN/A
    Fiscal years ended Dec 2018 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$187.77M$178.23M$168.23M$164.66M$163.62M$159.80M$164.00M$172.72M$179.18M$179.60M$204.53M$209.24M
    Total liabilities$225.13M$203.15M$184.51M$180.38M$175.89M$168.78M$158.93M$169.13M$163.70M$150.40M$163.24M$152.22M
    Cash and equivalents$36.90M$41.09M$30.28M$33.56M$27.66M$30.29M$39.74M$49.67M$47.40M$36.42M$36.05M$33.49M
    Shareholder equity-$37.35M-$24.91M-$16.29M-$15.72M-$12.27M-$8.98M$5.07M$3.59M$15.48M$29.21M$41.30M$57.02M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
    Operating cash flow-$24.59M-$26.54M-$36.31M-$61.76M-$32.68M$508.00K$3.62M$5.64M
    Capital expenditures$3.20M$3.79M$4.57M$5.53M$2.85M$1.19M$1.20M$695.96K
    Free cash flow-$27.79M-$30.33M-$40.88M-$67.28M-$35.53M-$686.00K$2.41M$4.95M
    Dividends paidN/AN/A$1N/AN/A$0N/A$8.20M
    Share repurchasesN/AN/A$1.02M$9.00M$0N/AN/AN/A
    Investing cash flow-$3.07M$46.21M$62.64M-$131.61M-$12.15M-$8.84M-$1.20M$2.49M
    Financing cash flow$11.56M-$3.49M-$6.85M$92.21M$154.01M$11.89M-$1.81K-$8.20M
    Fiscal years ended Dec 2018 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow$10.14M$11.94M-$2.21M$3.23M-$12.63M-$10.20M-$4.99M$4.19M$819.00K-$15.66M-$15.88M-$3.89M
    Capital expenditures$1.26M$908.00K$1.04M$1.06M$604.00K$1.21M$328.00K$1.75M$402.00K$1.83M$610.00K$861.00K
    Free cash flow$8.88M$11.03M-$3.26M$2.17M-$13.23M-$11.41M-$5.32M$2.43M$417.00K-$17.49M-$16.49M-$4.75M
    Last 12 quarters

    Frequently Asked Questions About TOI

    What is Oncology Institute's annual revenue?

    Oncology Institute reported revenue of $502.73M for the fiscal year ended Dec 31, 2025.

    How fast is Oncology Institute's revenue growing?

    Revenue was up 27.8% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 25.8%.

    Is Oncology Institute profitable?

    No. Oncology Institute reported net income of -$60.61M for the fiscal year ended Dec 31, 2025, with a net margin of -12.1%.

    How much free cash flow does TOI generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$24.59M minus capital expenditures of $3.20M produced free cash flow of -$27.79M.

    How much debt does Oncology Institute have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $77.40M, short-term debt of $50.32M and cash and equivalents of $33.56M.